CN114144418A - 喹唑啉类化合物的晶型、盐型及其制备方法 - Google Patents

喹唑啉类化合物的晶型、盐型及其制备方法 Download PDF

Info

Publication number
CN114144418A
CN114144418A CN202080044785.6A CN202080044785A CN114144418A CN 114144418 A CN114144418 A CN 114144418A CN 202080044785 A CN202080044785 A CN 202080044785A CN 114144418 A CN114144418 A CN 114144418A
Authority
CN
China
Prior art keywords
degrees
compound
formula
angles
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080044785.6A
Other languages
English (en)
Other versions
CN114144418B (zh
Inventor
陈新海
张丽
周凯
于衍新
胡伯羽
章晖宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHENGDU JINRUI JIYE BIO-TECHNOLOGY CO LTD
Original Assignee
Shenzhen Jinruijiye Biotechnology Co ltd
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Jinruijiye Biotechnology Co ltd, Medshine Discovery Inc filed Critical Shenzhen Jinruijiye Biotechnology Co ltd
Publication of CN114144418A publication Critical patent/CN114144418A/zh
Application granted granted Critical
Publication of CN114144418B publication Critical patent/CN114144418B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种作为Pan‑HER酪氨酸激酶抑制剂的化合物的晶型、盐型及其制备方法，并涉及其在制备治疗实体瘤的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (34)

  1. PCT国内申请，权利要求书已公开。
CN202080044785.6A 2019-06-19 2020-06-19 喹唑啉类化合物的晶型、盐型及其制备方法 Active CN114144418B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910533240.0 2019-06-19
CN201910533240 2019-06-19
PCT/CN2020/097158 WO2020253836A1 (zh) 2019-06-19 2020-06-19 喹唑啉类化合物的晶型、盐型及其制备方法

Publications (2)

Publication Number Publication Date
CN114144418A true CN114144418A (zh) 2022-03-04
CN114144418B CN114144418B (zh) 2023-10-10

Family

ID=74040641

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080044785.6A Active CN114144418B (zh) 2019-06-19 2020-06-19 喹唑啉类化合物的晶型、盐型及其制备方法

Country Status (5)

Country Link
US (1) US20220242851A1 (zh)
EP (1) EP3988553A4 (zh)
JP (1) JP7350374B2 (zh)
CN (1) CN114144418B (zh)
WO (1) WO2020253836A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117567466A (zh) * 2024-01-16 2024-02-20 成都金瑞基业生物科技有限公司 一种喹唑啉衍生物的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679384A (zh) * 2007-06-05 2010-03-24 韩美药品株式会社 用于抑制癌细胞生长的新酰胺衍生物
CN105461729A (zh) * 2015-11-18 2016-04-06 乳源瑶族自治县大众药品贸易有限公司 一种egfr抑制剂的盐、晶型及其用途
CN105555782A (zh) * 2013-09-28 2016-05-04 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
WO2019120213A1 (zh) * 2017-12-19 2019-06-27 南京明德新药研发股份有限公司 喹唑啉衍生物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6704422B2 (ja) * 2015-03-20 2020-06-03 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドＣｈｉａ Ｔａｉ Ｔｉａｎｑｉｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．，Ｌｔｄ． キナゾリン誘導体の塩およびその製造方法
US10308658B2 (en) * 2015-10-19 2019-06-04 Sunshine Lake Pharma Co., Ltd. Salt of EGFR inhibitor, crystalline form and uses thereof
CN105294717B (zh) * 2015-11-18 2017-12-22 乳源瑶族自治县大众药品贸易有限公司 一种egfr抑制剂的盐、晶型及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679384A (zh) * 2007-06-05 2010-03-24 韩美药品株式会社 用于抑制癌细胞生长的新酰胺衍生物
CN105555782A (zh) * 2013-09-28 2016-05-04 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
CN105461729A (zh) * 2015-11-18 2016-04-06 乳源瑶族自治县大众药品贸易有限公司 一种egfr抑制剂的盐、晶型及其用途
WO2019120213A1 (zh) * 2017-12-19 2019-06-27 南京明德新药研发股份有限公司 喹唑啉衍生物及其应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117567466A (zh) * 2024-01-16 2024-02-20 成都金瑞基业生物科技有限公司 一种喹唑啉衍生物的制备方法
CN117567466B (zh) * 2024-01-16 2024-04-16 成都金瑞基业生物科技有限公司 一种喹唑啉衍生物的制备方法

Also Published As

Publication number Publication date
EP3988553A1 (en) 2022-04-27
EP3988553A4 (en) 2023-06-14
JP2022537758A (ja) 2022-08-29
JP7350374B2 (ja) 2023-09-26
US20220242851A1 (en) 2022-08-04
CN114144418B (zh) 2023-10-10
WO2020253836A1 (zh) 2020-12-24

Similar Documents

Publication Publication Date Title
AU2018212647B2 (en) Combination therapy involving diaryl macrocyclic compounds
CN107108648B (zh) 作为ERK抑制剂的噻吩并[2,3-c]吡咯-4-酮衍生物
CN106928150B (zh) 丙烯酰胺苯胺衍生物及其药学上的应用
KR101174672B1 (ko) 항증식제로서의 피리도- 및 피리미도피리미딘 유도체
EP2491032B1 (en) Akt inhibitors
JP7312335B2 (ja) Ｂｒａｆ関連疾患および障害を処置するための４－オキソ－３，４－ジヒドロキナゾリノン化合物
Fan et al. Discovery of Dioxino [2, 3-f] quinazoline derivative VEGFR-2 inhibitors exerting significant antipro-liferative activity in HUVECs and mice
EP3102571A1 (en) Substituted pyrimidines useful as egfr-t790m kinase inhibitors
KR20210150476A (ko) 헤테로시클릭 화합물 및 그의 용도
CN114728957A (zh) 一种atr抑制剂的晶型及其应用
CN114144418A (zh) 喹唑啉类化合物的晶型、盐型及其制备方法
CN112351971B (zh) 喹啉或喹唑啉类化合物及其应用
JP2019513730A (ja) 癌を治療するためのＡＴＭ（毛細血管拡張性運動失調症変異）キナーゼモジュレータとしてのＮ，Ｎ−ジメチル−３−［［５−（３−メチル−２−オキソ−１−テトラヒドロピラン−４−イル−イミダゾ［４，５−ｃ］キノリン−８−イル）−２−ピリジル］オキシ］プロパン−１−アミンオキシド
CN115448874A (zh) 固体形式的周期蛋白依赖性激酶9抑制剂及其用途
EP3971175A1 (en) Crystal form of quinazolinone compound and preparation method therefor
WO2021088987A1 (zh) 作为选择性her2抑制剂的盐型、晶型及其应用
CN116018343A (zh) 一种吡啶并嘧啶化合物的晶型
CN114174269A (zh) 作用于egfr和erbb2的嘧啶类化合物
Wang et al. Discovery of unglycosylated indolocarbazoles as ROCK2 isoform-selective inhibitors for the treatment of breast cancer metastasis
CN116003406B (zh) 杂芳环氮氧化合物及其制备方法和应用
EP2896622B1 (en) Pi3k and/or mtor inhibitor
Cui et al. Structure optimization and discovery of novel compound for the treatment of insertion mutations within exon 20 of EGFR and HER2
WO2020224585A1 (zh) 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法
CN103772411A (zh) 含硫6-呋喃基喹唑啉-4-胺化合物及其制备方法和用途
CN105121442B (zh) PI3K和/或mTOR抑制剂的前药

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40065055

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20221205

Address after: No. 2004, 20th Floor, Building 1, No. 333, North Yizhou Avenue, Chengdu Hi tech Zone, China (Sichuan) Pilot Free Trade Zone, 610000, Sichuan

Applicant after: Chengdu Jinrui Jiye Bio-Technology Co.,Ltd.

Address before: 518118 innovation Plaza a2402, No. 2007, Pingshan Avenue, Liulian community, Pingshan street, Pingshan District, Shenzhen, Guangdong

Applicant before: Shenzhen jinruijiye Biotechnology Co.,Ltd.

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

GR01 Patent grant
GR01 Patent grant